menu
    • menu

    Company profile for Virupaksha Organics

    Virupaksha-PSE
    News
    Pharma Companies Expand In Kurnool, Boosting Andhra Pradesh

    09 Dec 2025

    // ECONOMICTIMES

    Virupaksha Organics Annual Report 2022 – 2023

    29 Sep 2025

    // PRESS RELEASE

    Virupaksha Organics Annual Report 2024 – 2025

    25 Sep 2025

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Virupaksha Organics

    Contact Supplier

    Website

    Chemspec Europe

    Booth #7E108

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.pharmacompass.com/video-supplier-spotlight/virupaksha-organics/corporate-video

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    Key Products KEY PRODUCTS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    With Virupaksha, you get a quality product with on-time delivery.

    Related CompaniesRelated Companies

    About

    Virupaksha Organics, founded in 2003, is a leading manufacturer of APIs and intermediates. Its FDA-audited, ISO-certified facilities in Kazipally and Pashamylaram produce high-quality products. With 300+ customers in 100 countries, Virupaksha has built a strong global presence and a trusted reputation for reliability.

    Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Virupaksha Organicsindia-flag Flag
    Country
    Country
    India
    Address
    Address
    IDA Industrial Area, Hyderabad Telangana, 500037
    Telephone
    Telephone
    +91 4023075816
    Client Email
    Email
    info@virupaksha.com
    Client Website
    Website
    https://virupaksha.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/virupaksha-organics-limited
    youtube
    YouTube
    https://www.youtube.com/channel/UCJC8cgBXIDFtn-4mcoJYkMA
    Twitter
    Twitter
    https://x.com/Virupaksha_hybd
    Contact Info
    Others

    Unit 1
    Sy.No.10, Gaddapotharam village, Jinnaram Mandal, Sangareddy Dist., Telangana, India

    Unit 2
    Plot no 30 to 33 IDA Pashamylaram Patancheru,Sangareddy Dist., Telangana, India

    Unit 3
    Plot no 100 (P2) & 100 (P3),Gadwanthi vil, Humnabad, Bidar, Karnataka, India

    KLPL
    Plot no 106(B)&107, Gadwanthi vil, Humnabad, Bidar, Karnataka, India

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    Chemspec Europe

    Booth #7E108

    envelop Contact Supplier

    Chemspec Europe

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/virupaksha-organics-party-content-16798.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/virupaksha-organics-party-content-27692.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/virupaksha-organics-party-content-35574.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    API Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/virupaksha-organics-party-content-55646.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Intermediates Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/virupaksha-organics-party-content-27772.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397  Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17   13 37 Taiwan 9 6 5 4 24 Switzerland 15 4   4 23 France 16     6 22 Japan 18   1   19 United Kingdom 12 1   2 15 Mexico 9 1   1 11 Ireland 5 5   1 11   Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 15977

    https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities

    #PharmaFlow by PHARMACOMPASS
    21 Nov 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Pharma Companies Expand In Kurnool, Boosting Andhra Pradesh
    Pharma Companies Expand In Kurnool, Boosting Andhra Pradesh

    09 Dec 2025

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/telanganas-loss-is-andhras-gain-as-pharma-companies-expand-in-kurnool/articleshow/125861978.cms

    ECONOMICTIMES
    09 Dec 2025
    Share Share
    Virupaksha Organics Annual Report 2022 – 2023
    Virupaksha Organics Annual Report 2022 – 2023

    29 Sep 2025

    // PRESS RELEASE

    https://virupaksha.com/wp-content/uploads/2025/09/VOL-Annual-Report-FY-22-23.pdf

    PRESS RELEASE
    29 Sep 2025
    Share Share
    Virupaksha Organics Annual Report 2024 – 2025
    Virupaksha Organics Annual Report 2024 – 2025

    25 Sep 2025

    // PRESS RELEASE

    https://virupaksha.com/wp-content/uploads/2025/09/VOL-Annual-Report-FY-24-25.pdf

    PRESS RELEASE
    25 Sep 2025
    Share Share
    Virupaksha Organics agreed to acquire 42.29% stake in Oxygenta
    Virupaksha Organics agreed to acquire 42.29% stake in Oxygenta

    30 Sep 2024

    // BSEINDIA

    https://www.bseindia.com/xml-data/corpfiling/AttachHis/1C45CF51-65B3-4DE7-B64C-CE5E996BBAD7-191527.pdf

    BSEINDIA
    30 Sep 2024
    Share Share
    Virupaksha Organics Annual Report 2023 – 2024
    Virupaksha Organics Annual Report 2023 – 2024

    28 Sep 2024

    // PRESS RELEASE

    https://virupaksha.com/wp-content/uploads/2025/09/VOL-Annual-Report-FY-23-24.pdf

    PRESS RELEASE
    28 Sep 2024
    Share Share

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    REF. STANDARDS & IMPURITIES

    Check the ref. standards & impurities from this company

    Inspections and registrations

    Check the inspections & registration from this company
    Virupaksha

    ABOUT THIS PAGE

    Contact Virupaksha Organics and get a quotation

    Virupaksha Organics is a supplier offers 39 products (APIs, Excipients or Intermediates).

    Find Fluconazole bulk with DMF, CEP, JDMF, WC offered by Virupaksha Organics

    Find Bilastine bulk with DMF, JDMF, WC offered by Virupaksha Organics

    Find Efinaconazole bulk with DMF, JDMF, WC offered by Virupaksha Organics

    Find Fexofenadine Hydrochloride bulk with DMF, JDMF, WC offered by Virupaksha Organics

    Find Tramadol Hydrochloride bulk with DMF, CEP, WC offered by Virupaksha Organics

    Find Citalopram Hydrobromide bulk with DMF, CEP offered by Virupaksha Organics

    Find Crisaborole bulk with DMF, WC offered by Virupaksha Organics

    Find Dextromethorphan Hydrobromide bulk with DMF, WC offered by Virupaksha Organics

    Find Escitalopram Oxalate bulk with DMF, CEP offered by Virupaksha Organics

    Find Fexofenadine Hydrochloride bulk with JDMF, WC offered by Virupaksha Organics

    Find Tapentadol bulk with CEP, WC offered by Virupaksha Organics

    Find Bempedoic Acid bulk with WC offered by Virupaksha Organics

    Find Fexofenadine Hydrochloride bulk with JDMF offered by Virupaksha Organics

    Find Fluconazole bulk with DMF offered by Virupaksha Organics

    Find Tafamidis bulk with WC offered by Virupaksha Organics

    Find Tafamidis Meglumine bulk with WC offered by Virupaksha Organics

    Find Tramadol Hydrochloride bulk with WC offered by Virupaksha Organics

    Find Vonoprazan Fumarate bulk with WC offered by Virupaksha Organics

    Find Fexofenadine hydrochloride, Non-micronised and micronised bulk with CEP offered by Virupaksha Organics

    Find Capsaicin bulk offered by Virupaksha Organics

    Find Chlorthalidone bulk offered by Virupaksha Organics

    Find Clopidogrel bulk offered by Virupaksha Organics

    Find Dextromethorphan bulk offered by Virupaksha Organics

    Find Efinaconazole bulk offered by Virupaksha Organics

    Find Etoricoxib bulk offered by Virupaksha Organics

    Find Fluconazole bulk offered by Virupaksha Organics

    Find Flurbiprofen bulk offered by Virupaksha Organics

    Find Imeglimin Hydrochloride bulk offered by Virupaksha Organics

    Find Isavuconazonium Sulfate bulk offered by Virupaksha Organics

    Find Ketamine Hydrochloride bulk offered by Virupaksha Organics

    Find Lacosamide bulk offered by Virupaksha Organics

    Find Levalbuterol Sulfate bulk offered by Virupaksha Organics

    Find Linagliptin bulk offered by Virupaksha Organics

    Find Ranolazine bulk offered by Virupaksha Organics

    Find Sacubitril-Valsartan bulk offered by Virupaksha Organics

    Find Salbutamol Sulphate bulk offered by Virupaksha Organics

    Find Tavaborole bulk offered by Virupaksha Organics

    Find Tramadol Hydrochloride bulk offered by Virupaksha Organics

    Find Vildagliptin bulk offered by Virupaksha Organics

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search